RxDoctor Payments Data

Holly Beck, DPM

Podiatrist · Silver Spring, MDNPI 1912938481

Payments from drug & device makers

What this record shows

This record is dominated by other: $14,000 of the $14,594 with a category attached, or 95.9%. Convatec Inc. accounts for 96.0% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2024 at $14,114 and has fallen 98.7% since, to $182 in 2025. Among podiatrist clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,594in general payments, 2019–2025

Across 27 payments — averaging $540.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Convatec Inc.$14K
  • Globus Medical$146
  • Cardiovascular Systems Inc.$144
  • Sebela Pharmaceuticals Inc.$89
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$52
  • Averitas Pharma Inc.$39
  • plus $107 from 6 others

What the payments were for

  • Food & beverage$5944%
  • Other$14,00096%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,594 in reported general payments places this provider in the 95th percentile of 183 podiatrist providers in Maryland.

See all podiatrist providers in Maryland

Medicare billing

Part B allowed, 2024
$300,660
Medicare patients
537
Services billed
4,424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole20$18,101
Ketoconazole133$3,312
Ciclopirox18$1,338
Ammonium Lactate34$727
Pregabalin22$503
Terbinafine Hcl43$470
Gabapentin26$192
Mupirocin16$174
Meloxicam20$65

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$52$18,10120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 183 podiatrist providers in Maryland.

Other podiatrist in Silver Spring

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →